Scope of Services
#
R&D Strategy & Phase Transitions
We structure development as a decision-making architecture.
Many programs fail not because of the science, but because critical decisions are made too late, on insufficient grounds, or without a clear strategic framework. We structure development around critical decision logics and integrate regulatory, clinical, and commercial requirements from the outset. This results in programs that are not only scientifically robust, but also investment-ready and executable.
Our Approach
We conceive of phase transitions as decision architecture.
Decision-driven development instead of trial and error.
Excellere does not act as a purely scientific sparring partner, but as an integrated strategic and operational advisor across critical development phases. We combine:
Decision Logic
Which decisions are required, when, and on what basis?
Evidence and Development Logic
Which data inform which strategic decisions?
Regulatory Alignment
Which requirements must be documented in a robust and decision-ready form?
Commercial Viability
Ensuring that clinical decisions translate into economically viable development paths.
Relevance for Companies and Investors
Decision-making quality in critical development phases.
Life Science Companies
For organizations that need to structure development programs not only on a scientifically sound basis, but also in a way that is investable and executable from the outset. Particularly relevant in phases where regulatory, clinical, and commercial requirements converge for the first time and missteps are still correctable.
Investors
For investors who seek to ensure that critical development decisions across their portfolio companies are made in a structured, traceable, and risk-conscious manner. Applied to de-risk phase transitions, assess assets, and strengthen decision quality in clinically and regulatorily complex situations.
Services across critical phase transitions
Structured development across critical decision-making phases.
EARLY RESEARCH THROUGH PRECLINICAL
Focus
Structuring the scientific hypothesis through clear translational logic and early validation of critical risks.
Regulatory Considerations
Early identification of core regulatory questions and preparation for Scientific Advice and pre-IND interactions to prevent downstream objections and ensure robust development pathways.
PRECLINICAL TO CLINICAL
Focus
Clinical entry readiness, robust study design, and definition of critical decision gates, embedded in a consistent CMC, nonclinical, and clinical decision-making framework.
Regulatory Considerations
Strategic preparation for regulatory interactions, including meeting and briefing strategies, as well as ensuring dossier-ready documentation for a robust clinical start.
CLINICAL TO COMMERCIAL PLANNING
Focus
Early integration of market access and commercial assumptions into clinical programs.
Regulatory Considerations
Ensuring that clinical endpoints, target populations, and evidence plans are regulatorily sound and form a consistent basis for reimbursement and value arguments.
OPERATIONALIZATION AND SCALING
Focus
Management of growing programs, partner ecosystems, governance structures, and decision-making architecture.
Regulatory Considerations
Scaling dossier readiness and documentation quality to ensure regulatory robustness, CMC consistency, and an industry-ready development structure.
Additional service areas
